证券代码：688161 证券简称：威高骨科 公告编号：2023-028 山东威高骨科材料股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）于2023年8月28日召开 第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于使用部 分闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集资金投资项 目实施、确保募集资金安全以及公司正常运营的前提下，使用不超过人民币9.5 亿元的暂时闲置募集资金进行现金管理，期限自第三届董事会第四次会议审议通 过之日起12个月，在决议有效期内资金额度可以循环滚动使用。 公司董事会授权公司董事长和管理层在上述额度范围及有效期内行使投资 决策权并签署相关合同等法律文件，具体事项由公司财务部负责组织实施。公司 独立董事发表了明确同意的意见，保荐机构华泰联合证券有限责任公司（以下简 称"保荐机构"）对本事项出具了明确同意的核查意见。 一、募集资金基本情况 经上海证券交易所科创板股票上市委 ...

山东威高骨科材料股份有限公司 关于以集中竞价交易方式回购公司股份预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 山东威高骨科材料股份有限公司（以下简称"公司"）本次以集中竞价交 易方式拟回购部分公司已发行的人民币普通股（A 股）股份，主要内容如下： 证券代码：688161 证券简称：威高骨科 公告编号：2023-033 1、拟回购股份的用途：用于实施员工持股及/或股权激励计划。若公司未能 在股份回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用 的已回购股份将予以注销。如国家对相关政策作调整，则本次回购股份方案按调 整后的政策实行。 2、回购规模：回购资金总额不低于人民币 6,000 万元（含），不超过人民 币 1.2 亿元（含）。 3、回购价格：不超过人民币 50 元/股（含），该价格不高于公司董事会通 过回购决议前 30 个交易日公司股票交易均价的 150%。 4、回购期限：本次回购股份的期限为自公司董事会审议通过本次回购股份 方案之日起 12 个月内。如果触及以下条件之一 ...

证券代码：688161 证券简称：威高骨科 公告编号：2023-031 山东威高骨科材料股份有限公司 第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司监事会认为：公司募集资金在 2023 年半年度的存放与使用符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》《上海证券交易所科创板股票上市规则》等相关法规和公司相关募集资金管 理制度的规定，公司募集资金存放于专项账户进行集中管理，并与保荐机构和相 关银行签署了募集资金专户存储监管协议。公司 2023 年半年度募集资金存放与 使用情况专项报告如实反映了公司 2023 年半年度募集资金存放与使用情况。 一、监事会召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届监事会第四次会 议于 2023 年 8 月 28 日以现场表决的方式在公司会议室召开。本次监事会会议通 知及会议材料已于 2023 年 8 月 18 日向公司全体监事发出。本次会议由监事会主 席陈柔姿女士主持，会议应出席监事 ...

山东威高骨科材料股份有限公司 关于参加2023 年半年度医疗器械及医疗设备行业 集体业绩说明会的公告 证券代码：688161 证券简称：威高骨科 公告编号：2023-026 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 9 月 5 日(星期二) 下午 13:00-15:00 会议召开方式：线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 4 日(星期一)16:00 前通过邮件、电话、传真等形 式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍 关注的问题进行回答。 山东威高骨科材料股份有限公司（以下简称"公司"）将于 2023 年 8 月 30 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 ...

证券代码：688161 证券简称：威高骨科 公告编号：2023-025 山东威高骨科材料股份有限公司 关于公司董事长提议公司回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到公司董事长弓剑波先生《关于提议山东威高骨科材料股份有限公司回购公 司股份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 公司董事长弓剑波先生基于对公司未来持续发展的信心和对公司价值的认 可，为了维护广大投资者利益，增强投资者对公司的投资信心，提高公司员工凝 聚力，增强公司员工的积极性，同时促进公司长期稳定健康发展，有效地将股东 利益、公司利益和员工个人利益紧密结合在一起，提议公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机全部用 于员工持股计划和股权激励计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A 股）。 2、回购股份的用途：用于员工持股及/或股权激励计划。若公司未能 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥389,781,832.60, representing a year-on-year increase of 0.57% compared to ¥387,574,619.74 in the same period last year[6]. - Net profit attributable to shareholders was ¥94,138,278.36, a decrease of 18.11% from ¥114,953,718.82 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥91,026,500.35, down 19.31% from ¥112,803,321.51 in the previous year[6]. - The company reported a basic and diluted earnings per share of ¥0.24, a decrease of 17.24% from ¥0.29 in the same period last year[19]. - Net profit for Q1 2023 was RMB 94,089,505.89, a decrease of 18.2% from RMB 114,908,534.45 in Q1 2022[54]. - The basic earnings per share for Q1 2023 was RMB 0.24, down from RMB 0.29 in Q1 2022[54]. Cash Flow and Liquidity - The net cash generated from operating activities was ¥33,368,877.54, down 81.60% from ¥181,308,485.82 in the same period last year[6]. - Cash inflow from operating activities for Q1 2023 was $495,753,784.36, a decrease of 12.8% compared to $568,437,515.99 in Q1 2022[56]. - Net cash flow from operating activities was $33,368,877.54, down 81.6% from $181,308,485.82 in the same period last year[56]. - Cash outflow from operating activities increased to $462,384,906.82, up 19.4% from $387,129,030.17 in Q1 2022[56]. - Cash and cash equivalents at the end of Q1 2023 were $2,049,281,131.87, down from $2,742,430,707.67 at the end of Q1 2022[57]. - The company reported a significant increase in cash paid for purchasing goods and services, which rose to $104,744,099.73 from $58,210,369.65 in Q1 2022[56]. - The company’s cash flow from other operating activities decreased to $21,584,208.94 from $70,658,125.78 in Q1 2022, highlighting a decline in ancillary income sources[56]. Research and Development - R&D investment totaled ¥27,331,141.04, which is 7.01% of operating revenue, an increase of 1.83 percentage points compared to the previous year[19]. - R&D investment increased by 36.21%, indicating a significant rise in technology development efforts[41]. - Research and development expenses increased to RMB 27,331,141.04 in Q1 2023, compared to RMB 20,064,957.67 in Q1 2022, reflecting a growth of 36.4%[54]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,431,681,083.51, a decrease of 9.70% from the previous year[19]. - The total assets decreased from 6,015,055,250.84 to 5,431,681,083.51, representing a decline of approximately 9.7%[30]. - The total current assets decreased from 5,248,998,758.00 to 4,674,642,163.22, a reduction of about 10.9%[30]. - The total liabilities as of March 31, 2023, were RMB 1,361,102,469.75, an increase from RMB 1,008,842,421.97 as of December 31, 2022[52]. - The company's total equity decreased to RMB 4,070,578,613.76 as of March 31, 2023, down from RMB 5,006,212,828.87 at the end of 2022[52]. - The equity attributable to shareholders decreased by 18.69% due to the acquisition of a subsidiary under common control, which reduced the capital reserve[41]. Business Development and Strategy - The company launched new products, including the "PEEK cranial plate" and "absorbable interface screws," enhancing its offerings in neurosurgery and sports medicine[26][27]. - The company is transforming its sales model to improve terminal surgical volumes by establishing a nationwide logistics distribution network[26]. - The company is expanding into new business areas in orthopedics, particularly in sports medicine and neurosurgery, to support ongoing development[45]. - The company is leveraging its advantages in production lines and brand diversity to enhance market share amid centralized procurement initiatives[45]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[54].

证券代码：688161 证券简称：威高骨科 公告编号：2023-016 山东威高骨科材料股份有限公司 会议召开时间：2023 年 4 月 28 日（星期五）上午 09:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 21 日（星期五）至 4 月 27 日（星期四）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@wegortho.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 （一） 会议召开时间：2023 年 4 月 28 日上午 09:00-11:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 董事长：弓剑波 总经理：卢均强 董事会秘书：林青 财务总监：辛文智 独立董事：曲国霞 （如有特殊情况，参会人员将可能进行调整） 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 ...

Financial Performance - The company achieved operating revenue of 1,848.12 million yuan, a year-on-year decrease of 14.18%[17] - The net profit attributable to shareholders was 544.21 million yuan, down 21.17% year-on-year[17] - The company's operating revenue decreased by RMB 305.43 million, a decline of 14.18%, primarily due to cautious purchasing by distributors influenced by volume-based procurement[35] - The net cash flow from operating activities decreased by RMB 344.71 million, a decline of 43.73%, attributed to the reduction in operating revenue[35] - The company's operating revenue for the reporting period was 184.81 million yuan, a year-on-year decrease of 14.18%, primarily due to the impact of volume-based procurement policies[83] - The gross profit margin for trauma products decreased by 31.57%, primarily due to centralized procurement and a decline in terminal prices[108] - The company reported a net cash flow from operating activities of ¥443,538,409.59, a decrease of 43.73% from ¥788,251,164.57 in the previous year[104] - The net cash flow from investment activities improved by 85.97%, from -¥1,187,980,405.02 to -¥166,636,119.74[139] - The net cash flow from financing activities decreased significantly by 116.89%, from ¥1,353,615,047.31 to -¥228,675,762.62[139] Market Position and Product Development - In the spine sector, the company reported a total of approximately 141,000 units, maintaining the industry’s leading position, with all products successfully bid in the national procurement[18] - The trauma sector saw a total of approximately 266,000 units reported, further increasing market share[18] - The company’s joint brands achieved a surgical demand of about 52,000 units, accounting for 9% of the national procurement demand, with a 36.8% increase compared to pre-procurement surgical volumes[18] - The company is actively exploring new business lines and improving its product offerings in orthopedic rehabilitation and minimally invasive surgical equipment[19] - The company has established a presence in over 3,500 hospitals nationwide, indicating a strong market penetration and competitive positioning[56] - The company is focusing on the orthopedic implant medical device sector and aims to become a leading supplier of orthopedic consumables solutions globally[147] - The implementation of national volume-based procurement has led to significant changes in the industry landscape, with domestic brands gaining market share[159] Research and Development - The company is advancing over 100 research projects in new materials and technologies, including breakthroughs in new bone cement and biodegradable magnesium alloys[19] - The company achieved a total R&D investment of ¥107,766,860.12, a decrease of 11.10% compared to the previous year[64] - R&D investment accounted for 5.83% of total revenue, an increase of 0.2 percentage points from the previous year[64] - The company has obtained 13 Class I product filing certificates, 4 Class II medical device registration certificates, and 28 Class III medical device registration certificates during the reporting period[63] - The company holds 51 domestic and 2 international invention patents, along with 232 Class I product records and 97 Class III medical device registrations, indicating a strong R&D capability[69] - The company applied for a total of 45 patents during the reporting period, with 49 patents granted, bringing the cumulative total to 400 patents[84] Technology and Innovation - The company is implementing a digital factory strategy focused on lean production, automation, and digitalization to enhance production efficiency and cost control[20] - The company has developed a semi-open elastic arm for minimally invasive surgery, which reduces incision size to 13mm, minimizing tissue damage and improving recovery time[46] - The integrated mixing and injection technology for bone cement significantly reduces the release of irritating odors and simplifies the operational process, enhancing efficiency[46] - The locking bone fixation technology allows for stable fixation of fractures without relying on bone friction, improving blood circulation and recovery[47] - The intramedullary nail system reduces infection rates and preserves blood supply to the bone, facilitating quicker recovery for patients[47] - The development of 3D printing technology enhances surgical precision and meets the demand for personalized orthopedic implants[56] - The focus on biodegradable materials for orthopedic implants is expected to become a new profit growth point for the company[56] Strategic Partnerships and Collaborations - The company has established a strategic partnership with Beijing Tianzhihang Medical Technology Co., Ltd. for the development and application of orthopedic surgical robots, aiming to create next-generation orthopedic products suitable for robotic operations[42] - The company has established partnerships with over 2,000 distributors, covering more than 3,500 medical institutions nationwide, enhancing market reach[70] Operational Efficiency and Management - The marketing management department is enhancing sales service levels through timely updates and analysis of customer and sales data[18] - The company is actively pursuing lean production and digital transformation to mitigate risks associated with price declines due to national procurement policies[78] - The company plans to enhance its warehouse management platform and establish a big data center to improve production and sales data integration[99] - The company is integrating its distributor resources and implementing classified management to adapt to the volume-based procurement environment[97] - The company has established a comprehensive quality management system and has obtained ISO9001 and ISO13485 certifications, ensuring product reliability and stability[91] Human Resources and Corporate Governance - The total number of employees in the parent company is 1,613, with a total of 2,047 employees across the parent and major subsidiaries[195] - The company has a total of 1,099 production personnel, 553 sales personnel, 262 technical personnel, 52 financial personnel, and 81 administrative personnel[196] - The company has established a compensation incentive system to ensure the motivation, fairness, and competitiveness of salaries, enhancing employee engagement and creativity[197] - The company conducts targeted training programs for different teams, focusing on improving management quality and leadership skills[198] - The company has implemented a performance management system to clarify performance responsibilities and assessment indicators for all levels of staff[197] - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among various governance bodies[169] Future Outlook and Growth Strategies - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product portfolio[181] - The company plans to expand its operations into new international markets, targeting a 20% increase in overseas sales by the end of the fiscal year[181] - The company has launched a new line of orthopedic implants, which is expected to contribute an additional $50 million in revenue over the next year[181] - The company is focusing on enhancing its digital health solutions, aiming for a 30% increase in user engagement through new technology[181] - The company has set a performance guidance of 10-12% revenue growth for the upcoming fiscal year, reflecting its optimistic outlook[181] - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 25% over the next five years[181]

Financial Performance - The company's operating revenue for Q3 2022 was ¥287,805,032.83, a decrease of 39.44% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥44,329,095.50, down 64.59% year-on-year[7]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥41,592,203.43, a decline of 65.40% compared to the previous year[11]. - The basic earnings per share for Q3 2022 was ¥0.11, a decrease of 64.52% year-on-year[11]. - The company's total revenue for the first three quarters of 2022 was RMB 1,393,031,318.98, a decrease of approximately 11.3% compared to RMB 1,570,592,770.80 in the same period of 2021[31]. - Total operating revenue for the first three quarters of 2022 was CNY 1,555,852,228.04, a decrease from CNY 1,714,941,327.13 in the same period of 2021, representing a decline of approximately 9.3%[42]. - Net profit for the third quarter of 2022 was CNY 441,974,346.24, down from CNY 495,867,418.87 in the same quarter of 2021, reflecting a decrease of about 10.9%[38]. - The total profit for the third quarter of 2022 was CNY 511,330,868.13, down from CNY 587,118,379.80 in the same quarter of 2021, a decrease of about 12.9%[38]. - The total comprehensive income for the third quarter of 2022 was CNY 441,974,346.24, compared to CNY 495,867,418.87 in the same quarter of 2021, reflecting a decrease of about 10.9%[40]. Expenses and Costs - Research and development expenses totaled ¥27,373,135.34 in Q3 2022, representing 9.51% of operating revenue, an increase of 3.05 percentage points from the previous year[11]. - Total operating costs for the third quarter of 2022 were CNY 906,008,818.56, down from CNY 983,109,988.75 in the previous year, a reduction of about 7.8%[38]. - Research and development expenses for the third quarter of 2022 were CNY 83,299,404.36, slightly up from CNY 81,678,494.11 in the same quarter of 2021, an increase of approximately 2.0%[38]. - The company reported a financial expense of CNY -30,263,287.56 in the third quarter of 2022, compared to CNY -21,502,639.59 in the same quarter of 2021, indicating a worsening of financial costs[38]. - Tax expenses for the third quarter of 2022 were CNY 69,356,521.89, down from CNY 91,250,960.93 in the same quarter of 2021, a decrease of approximately 24.0%[38]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥5,618,569,023.82, an increase of 3.98% compared to the end of the previous year[11]. - The company's total equity attributable to shareholders increased by 5.23% year-on-year, reaching ¥4,768,548,730.81[11]. - The total liabilities of the company as of September 30, 2022, were RMB 849,859,015.88, a slight decrease from RMB 865,641,860.04 at the end of 2021[30]. - The company's inventory as of September 30, 2022, was RMB 652,425,162.50, up from RMB 564,900,238.24 at the end of 2021, indicating an increase of approximately 15.5%[26]. - The total equity attributable to shareholders as of September 30, 2022, was RMB 4,768,548,730.81, an increase from RMB 4,531,539,606.55 at the end of 2021, reflecting a growth of approximately 5.2%[30]. Cash Flow - The company's cash flow from operating activities for the year-to-date period decreased by 43.08% due to reduced sales receipts[11]. - The net cash flow from operating activities was 297,196,299.48, a decrease of 43% compared to 522,133,081.74 from the previous period[45]. - The total cash outflow from operating activities amounted to 1,258,655,928.56, up from 1,192,808,245.39, indicating a 5.5% increase[45]. - The net cash flow from investing activities was 12,592,467.71, recovering from a negative cash flow of -90,847,230.13 in the previous period[45]. - The net cash flow from financing activities was -223,611,921.07, a sharp decline from 1,374,176,588.27 in the previous period[47]. - The ending balance of cash and cash equivalents was 2,641,597,405.24, down from 3,406,327,136.38 in the previous period[47]. - The company paid 211,442,497.13 in dividends and interest, compared to no payments in the previous period[45]. - The cash outflow for investment activities was 493,425,540.15, a significant increase from 92,088,678.57 in the previous period[45]. - The company received 13,886,140.13 from financing activities, a decrease from 1,404,644,965.51 in the previous period[45]. - The cash flow from other investment activities increased to 3,679,117.10 from 1,160,227.20 in the previous period[45]. Market Position and Strategy - The decline in operating revenue was attributed to cautious purchasing behavior from downstream terminals and distributors amid ongoing national volume-based procurement for spinal products[14]. - The company successfully won all bids in the national centralized procurement of orthopedic spinal consumables announced on September 30, 2022, which is expected to enhance market share[22]. - The company plans to continue focusing on innovation and product development in the orthopedic medical device sector to strengthen its market position[22]. - The company maintains a multi-brand strategy to enhance its market share across various segments in the orthopedic field[22]. - The company's net profit for the first three quarters of 2022 is not explicitly stated, but the decrease in total revenue suggests potential challenges in profitability[31].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 1,105,226,286.15, a year-on-year increase of 0.90% compared to RMB 1,095,315,818.33 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was RMB 397,978,394.23, reflecting a year-on-year growth of 7.81% from RMB 369,150,481.23[21]. - The net cash flow from operating activities decreased by 10.78%, amounting to RMB 363,815,020.95, down from RMB 407,784,522.96 in the previous year[21]. - The total assets as of June 30, 2022, were RMB 5,753,044,252.81, representing a 6.47% increase from RMB 5,403,274,095.25 at the end of the previous year[23]. - The company's net assets attributable to shareholders increased by 4.22% to RMB 4,722,837,010.78 from RMB 4,531,539,606.55 at the end of the previous year[21]. - Basic earnings per share for the first half of 2022 were RMB 0.99, a decrease of 3.88% compared to RMB 1.03 in the same period last year[24]. - The overall gross profit margin for the reporting period was 78.37%[33]. Research and Development - The R&D investment as a percentage of operating revenue increased by 0.40 percentage points to 5.06%[24]. - R&D expenses totaled ¥55,926,269.02, an increase of 9.68% compared to ¥50,991,443.15 from the previous year[55]. - The company has 264 R&D personnel, representing 12.85% of total employees, an increase from 12.00% last year[62]. - The company has established a complete, independent, and mature R&D technology system in the orthopedic implant field, demonstrating its capability for innovation[41]. - The company is focused on continuous product innovation and technical breakthroughs in the orthopedic implant medical device field, emphasizing the importance of R&D investment[51]. Market Position and Strategy - The company maintains a leading market position in the orthopedic implant medical device sector, with a strong competitive edge against foreign enterprises[38]. - The orthopedic implant medical device market in China grew from 16.4 billion yuan in 2015 to 30.8 billion yuan in 2019, with a compound annual growth rate of 17.03%[29]. - The company continues to expand its product line, covering spinal, trauma, joint, and sports medicine segments[30]. - The company emphasizes collaboration with medical institutions and clinical doctors to enhance product innovation and market reach[34]. Risks and Challenges - The company has detailed the major risks and countermeasures it will face in the future within the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[4]. - The company faces risks related to new product development and market promotion, including potential failures in meeting regulatory standards[78]. - The ongoing COVID-19 pandemic poses risks to the company's operations, affecting customer and distributor activities, which may lead to reduced surgical volumes[81]. Corporate Governance - The board of directors confirmed that all members attended the board meeting, ensuring the authenticity and completeness of the semi-annual report[4]. - The semi-annual report has not been audited, but the responsible persons have declared the financial report's authenticity and completeness[4]. - The company has not made any special arrangements for corporate governance during this reporting period[4]. - There are ongoing commitments to reduce related party transactions to enhance corporate governance[115]. Shareholder Commitments and Profit Distribution - The company has a profit distribution policy in place, with commitments to ensure transparency and accountability[112]. - The profit distribution policy emphasizes cash dividends, with a minimum cash dividend ratio of 80% for mature companies without major capital expenditures[176]. - The company will ensure that the profit distribution plan is executed within two months after the shareholders' meeting resolution[176]. - The company commits to compensating investors for losses caused by false statements in the prospectus[149]. Environmental and Social Responsibility - The company has not experienced any significant environmental incidents or penalties during the reporting period, adhering to environmental protection laws and regulations[104]. - The company has implemented strict internal environmental management standards, ensuring pollutant emissions comply with relevant standards[104]. - The company has not reported any measures taken to reduce carbon emissions during the reporting period[108].